



MDR-TB COUNTRY PROFILE




Kazakhstan has a population of 17 million and is one of the high multidrug-resistant TB (MDR-TB) burden countries globally. As a major partner, the U.S. Agency for International Development (USAID) has been providing critical technical support to the National TB and MDR-TB control program to effectively diagnose and treat TB and decrease the disease burden.

Number of notified TB patients in 2014: 15,974

Estimated MDR-TB cases: 10,000


** Estimates of MDR-TB cases are provisional, pending a review of methods by a WHO Task Force scheduled for April 2016 and subsequent review of estimates by national TB programs in July 2016.*

MDR-TB Detection and Enrollment on Treatment




MDR-TB detection and enrollment varied from 2009–2014. In 2014, the number of people enrolled on treatment was about 75 percent of the estimated number of cases, a marked increase from previous years.

MDR-TB Treatment Success Rate



The MDR-TB success rate has remained steady in the years 2007–2012; an average of 74 percent over the past 6 years.

Laboratory Capacity and Detection of MDR-TB



Kazakhstan has seen a rapid scale-up of GeneXpert sites in the country, growing from 4 to 22 from 2012–2014.

* 2012 data are the latest available for treatment success due to length of treatment.